# Dasatinib in Advanced Squamous Cell Lung Cancer

> **NCT01491633** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 5 (actual)

## Conditions studied

- Squamous Cell Lung Cancer

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT01491633
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09
- **Primary completion:** 2013-01
- **Final completion:** 2013-05
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Safety issues/concerns per DF/HCC PI
- **Last updated:** 2014-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01491633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01491633, "Dasatinib in Advanced Squamous Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01491633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*